On the stock market since 2007, it operates in the world of money and finance. It has 204 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $139.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 36 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $2.50 — 2,499,900% above today’s price.
A loss of $179K against $139.8M in annual sales.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, FPAYQ sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: FPAYQ is a high-risk stock — not yet profitable, and its future rides on its product catching on.